Richmond Pharmacology is pleased to confirm our attendance at The Liver Meeting 2025, hosted by the American Association for the Study of Liver Diseases (AASLD), taking place in Washington, DC, from 7–11 November.
Representing Richmond at The Liver Meeting:
James Rickard, Chief Scientific Officer James looks forward to engaging with industry and academic partners to discuss Richmond’s expertise in:
Early-phase hepatology and metabolic liver disease trials
First-in-human and dose-ranging studies
Non-invasive biomarkers and digital health integration
Regulatory strategy and multi-regional trial delivery
Patient-focused approaches in complex liver studies
If you’re attending AASLD 2025 and seeking a clinical development partner in liver disease research, get in touch to arrange a meeting with James: info@richmondpharmacology.com
Medicines Marketing UK / EU vs US: Why Your Launch Strategy Needs a Continental Divide - Dr Lisa Campbell, Director of Regulatory Strategy
September 12, 2025
A UK CRO’s perspective on planning clinical trials for global success For pharmaceutical companies preparing for global expansion, launching in both the US and EU / UK markets often seems like the natural next step. Yet success in one region does not guarantee success in the other.
Richmond Pharmacology will attend JSCPT 2025 in Tokyo, represented by their leadership team. Topics include early-phase studies, bridging studies between Europe and Asia, gene and RNA-based therapy development, and cross-border collaboration.
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
